Edesa Biotech, Inc. (EDSA): R&D Expense
$3.67M
Year ended 2025-09-30
$9.08M
Trailing 12 months to 2026-06-30
-35.0%
3-year compound annual growth
+2.0%
5-year compound annual growth
+13.6%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $3.67M | +27.3% | 2025-12-12, From 2024-10-01 |
| 2024-09-30 | $2.88M | -39.9% | 2025-12-12, From 2023-10-01 |
| 2023-09-30 | $4.79M | -64.0% | 2024-12-13, From 2022-10-01 |
| 2022-09-30 | $13.34M | -25.7% | 2023-12-15, From 2021-10-01 |
| 2021-09-30 | $17.95M | +439.0% | 2022-12-16, From 2020-10-01 |
| 2020-09-30 | $3.33M | n/a | 2021-12-28, From 2019-10-01 |
| No annual figure between 2018-09-30 and 2020-09-30. | |||
| 2018-09-30 | $2.09M | +5.8% | 2018-11-30, From 2017-10-01 |
| 2017-09-30 | $1.97M | +14.1% | 2018-11-30, From 2016-10-01 |
| 2016-09-30 | $1.73M | +68.0% | 2017-12-01, From 2015-10-01 |
| 2015-09-30 | $1.03M | n/a | 2017-12-01, From 2014-10-01 |
| 2014-08-31 | $2.46M | +21.8% | 2016-12-14, From 2013-09-01 |
| 2013-08-31 | $2.02M | -23.4% | 2015-12-14, From 2012-09-01 |
| 2012-08-31 | $2.63M | n/a | 2014-11-21, From 2011-09-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | 2025-09-30 | $3.67M | +27.3% |
| CalciMedica, Inc. (CALC) | 2025-12-31 | $15.23M | +5.2% |
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $5.83M | -48.5% |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $10.29M | -44.9% |
| Exicure, Inc. (XCUR) | 2025-12-31 | $3.29M | n/a |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $3.78M | -39.1% |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $147.0K | +40.5% |
| Biovie Inc. (BIVI) | 2026-06-30 | $13.96M | +50.7% |
| Propanc Biopharma, Inc. (PPCB) | 2026-06-30 | $625.5K | +179.6% |
Compare EDSA, CALC, CMMB, ACTU side by side · Screen every company in Pharmaceutical Preparations ↗